“Nothing to do with geopolitics”: WuXi Biologics CEO bullish in face of Biosecure
At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling effect on clients.
Fiona Barry, January 16, 2025
https://www.pharmaceutical-technology.com/...sh-in-face-of-biosecure/
-
Efforts revived to stem flow of US funding for China R&D
Feb. 10, 2025 By Mari Serebrov
"The Biosecure Act may have died with the 118th U.S. Congress, but efforts to stop U.S. government funding of R&D in China are alive and well. Rep. Claudia Tenney, R-N.Y., introduced the Stop Funding our Adversaries Act in the House Feb. 7 to prohibit direct and indirect federal funding of research in China or entities owned by China."
https://www.bioworld.com/articles/...ding-for-china-r-and-d?v=preview
-
07.02.2025
- U.S. likely to re-enact BIOSECURE Act this year to limit Chinese biotech firms
- If BIOSECURE Act is passed, Korean CDMO companies could benefit
- Chinese companies may look to establish corporations to bypass BIOSECURE Acts in the U.S.
https://www.thebionews.net/news/articleView.html?idxno=12601 |
1
|
